{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:24:20Z","timestamp":1790688260699,"version":"4.1.0"},"reference-count":31,"publisher":"American Diabetes Association","issue":"2","license":[{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"vor","delay-in-days":38,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:p>Lipodystrophies are a group of disorders characterized by absence or loss of adipose tissue and abnormal fat distribution, commonly accompanied by metabolic dysregulation. Although considered rare disorders, their prevalence in the general population is not well understood. We aimed to evaluate the clinical and genetic prevalence of lipodystrophy disorders in a large clinical care cohort. We interrogated the electronic health record (EHR) information of &amp;gt;1.3 million adults from the Geisinger Health System for lipodystrophy diagnostic codes. We estimate a clinical prevalence of disease of 1 in 20,000 individuals. We performed genetic analyses in individuals with available genomic data to identify variants associated with inherited lipodystrophies and examined their EHR for comorbidities associated with lipodystrophy. We identified 16 individuals carrying the p.R482Q pathogenic variant in LMNA associated with Dunnigan familial partial lipodystrophy. Four had a clinical diagnosis of lipodystrophy, whereas the remaining had no documented clinical diagnosis despite having accompanying metabolic abnormalities. We observed a lipodystrophy-associated variant carrier frequency of 1 in 3,082 individuals in our cohort with substantial burden of metabolic dysregulation. We estimate a genetic prevalence of disease of \u223c1 in 7,000 in the general population. Partial lipodystrophy is an underdiagnosed condition. and its prevalence, as defined molecularly, is higher than previously reported. Genetically guided stratification of patients with common metabolic disorders, like diabetes and dyslipidemia, is an important step toward precision medicine.<\/jats:p>","DOI":"10.2337\/db19-0447","type":"journal-article","created":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T01:05:52Z","timestamp":1576285552000},"page":"249-258","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":92,"title":["Clinical and Molecular Prevalence of Lipodystrophy in an Unascertained Large Clinical Care Cohort"],"prefix":"10.2337","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4667-3679","authenticated-orcid":false,"given":"Claudia","family":"Gonzaga-Jauregui","sequence":"first","affiliation":[{"name":"Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc., Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhen","family":"Ge","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Staples","sequence":"additional","affiliation":[{"name":"Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc., Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristopher","family":"Van Hout","sequence":"additional","affiliation":[{"name":"Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc., Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Yadav","sequence":"additional","affiliation":[{"name":"Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc., Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Colonie","sequence":"additional","affiliation":[{"name":"Geisinger Health System, Danville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B.","family":"Leader","sequence":"additional","affiliation":[{"name":"Geisinger Health System, Danville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Lester","family":"Kirchner","sequence":"additional","affiliation":[{"name":"Geisinger Health System, Danville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Murray","sequence":"additional","affiliation":[{"name":"Geisinger Health System, Danville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey G.","family":"Reid","sequence":"additional","affiliation":[{"name":"Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc., Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Carey","sequence":"additional","affiliation":[{"name":"Geisinger Health System, Danville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Overton","sequence":"additional","affiliation":[{"name":"Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc., Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R.","family":"Shuldiner","sequence":"additional","affiliation":[{"name":"Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc., Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omri","family":"Gottesman","sequence":"additional","affiliation":[{"name":"Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc., Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Gao","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Gromada","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aris","family":"Baras","sequence":"additional","affiliation":[{"name":"Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc., Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Altarejos","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2019,12,13]]},"reference":[{"key":"2022031210415441600_B1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.genom.7.080505.115715","article-title":"Genetic disorders of adipose tissue development, differentiation, and death","volume":"7","author":"Agarwal","year":"2006","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"2022031210415441600_B2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pathol.2018.11.004","article-title":"Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease","volume":"51","author":"Hussain","year":"2019","journal-title":"Pathology"},{"key":"2022031210415441600_B3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11892-018-1099-9","article-title":"Phenotypic and genetic characteristics of lipodystrophy: pathophysiology, metabolic abnormalities, and comorbidities","volume":"18","author":"Akinci","year":"2018","journal-title":"Curr Diab Rep"},{"key":"2022031210415441600_B4","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"key":"2022031210415441600_B5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ecl.2016.06.012","article-title":"Lipodystrophy syndromes","volume":"45","author":"Hussain","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2022031210415441600_B6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/jc.2016-2271","article-title":"Clinical features and management of non-HIV-related lipodystrophy in children: a systematic review","volume":"102","author":"Gupta","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031210415441600_B7","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Clinical review#: lipodystrophies: genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031210415441600_B8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2147\/DMSO.S130810","article-title":"Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges","volume":"10","author":"Chiquette","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2022031210415441600_B9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbalip.2008.12.014","article-title":"Lipodystrophies: disorders of adipose tissue biology","volume":"1791","author":"Garg","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"2022031210415441600_B10","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/47254","article-title":"Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension","volume":"402","author":"Barroso","year":"1999","journal-title":"Nature"},{"key":"2022031210415441600_B11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/72807","article-title":"LMNA, encoding lamin A\/C, is mutated in partial lipodystrophy","volume":"24","author":"Shackleton","year":"2000","journal-title":"Nat Genet"},{"key":"2022031210415441600_B12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/ng585","article-title":"Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13","volume":"28","author":"Magr\u00e9","year":"2001","journal-title":"Nat Genet"},{"key":"2022031210415441600_B13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ng880","article-title":"AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34","volume":"31","author":"Agarwal","year":"2002","journal-title":"Nat Genet"},{"key":"2022031210415441600_B14","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2337\/diabetes.52.4.910","article-title":"Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-\u03b3","volume":"52","author":"Savage","year":"2003","journal-title":"Diabetes"},{"key":"2022031210415441600_B15","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1007487","article-title":"Perilipin deficiency and autosomal dominant partial lipodystrophy","volume":"364","author":"Gandotra","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031210415441600_B16","doi-asserted-by":"crossref","DOI":"10.1038\/ejhg.2016.102","article-title":"Clinical Utility Gene Card for: familial partial lipodystrophy","volume":"25","author":"J\u00e9ru","year":"2017","journal-title":"Eur J Hum Genet"},{"key":"2022031210415441600_B17","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1172\/JCI129190","article-title":"What lipodystrophies teach us about the metabolic syndrome","volume":"130","author":"Mann","year":"2019","journal-title":"J Clin Invest"},{"key":"2022031210415441600_B18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ymgme.2005.10.018","article-title":"Laminopathies: multisystem dystrophy syndromes","volume":"87","author":"Jacob","year":"2006","journal-title":"Mol Genet Metab"},{"key":"2022031210415441600_B19","doi-asserted-by":"crossref","first-page":"aaf6814","DOI":"10.1126\/science.aaf6814","article-title":"Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study","volume":"354","author":"Dewey","year":"2016","journal-title":"Science"},{"key":"2022031210415441600_B20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/hmg\/9.1.109","article-title":"Nuclear lamin A\/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy","volume":"9","author":"Cao","year":"2000","journal-title":"Hum Mol Genet"},{"key":"2022031210415441600_B21","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1101\/gr.10.5.652","article-title":"Association between nuclear lamin A\/C R482Q mutation and partial lipodystrophy with hyperinsulinemia, dyslipidemia, hypertension, and diabetes","volume":"10","author":"Hegele","year":"2000","journal-title":"Genome Res"},{"key":"2022031210415441600_B22","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1086\/302836","article-title":"Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A\/C","volume":"66","author":"Speckman","year":"2000","journal-title":"Am J Hum Genet"},{"key":"2022031210415441600_B23","first-page":"59","article-title":"Phenotypic heterogeneity in patients with familial partial lipodystrophy (dunnigan variety) related to the site of missense mutations in lamin a\/c gene","volume":"86","author":"Garg","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031210415441600_B24","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ajhg.2018.03.012","article-title":"Profiling and leveraging relatedness in a precision medicine cohort of 92,455 exomes","volume":"102","author":"Staples","year":"2018","journal-title":"Am J Hum Genet"},{"key":"2022031210415441600_B25","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1210\/jc.2006-1807","article-title":"Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma","volume":"92","author":"Monajemi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031210415441600_B26","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/ng.3700","article-title":"Prospective functional classification of all possible missense variants in PPARG","volume":"48","author":"Majithia","year":"2016","journal-title":"Nat Genet"},{"key":"2022031210415441600_B27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","article-title":"Analysis of protein-coding genetic variation in 60,706 humans","volume":"536","author":"Lek","year":"2016","journal-title":"Nature"},{"key":"2022031210415441600_B28","first-page":"3089","article-title":"LMNA R482Q mutation in partial lipodystrophy associated with reduced plasma leptin concentration","volume":"85","author":"Hegele","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031210415441600_B29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/gim.2016.190","article-title":"Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics","volume":"19","author":"Kalia","year":"2017","journal-title":"Genet Med"},{"key":"2022031210415441600_B30","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/gim.2013.73","article-title":"ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing","volume":"15","author":"Green","year":"2013","journal-title":"Genet Med"},{"key":"2022031210415441600_B31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ajhg.2018.07.009","article-title":"A model for genome-first care: returning secondary genomic findings to participants and their healthcare providers in a large research cohort","volume":"103","author":"Schwartz","year":"2018","journal-title":"Am J Hum Genet"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/69\/2\/249\/431468\/db190447.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/69\/2\/249\/431468\/db190447.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T12:38:49Z","timestamp":1667392729000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/69\/2\/249\/16175\/Clinical-and-Molecular-Prevalence-of-Lipodystrophy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,13]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,12,13]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db19-0447","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,13]]}}}